Viral Infections and Antiviral Therapies

Dr. Amal Kumar Dhara has over 27 years of teaching and research experience in Pharmacology and Toxicology, with expertise in neuropharmacology, anti-inflammatory, antiulcer, and free radical scavenging activities of Indian medicinal plants. He earned his PhD in Pharmaceutical Sciences from Jadavpur University, Kolkata, West Bengal, India. Dr. Dhara currently serves as Head of the Department (Pharmacy) at Contai Polytechnic, Government of West Bengal, India. He has previously worked as a Production Executive at M/S Deys Medical Stores Mfg (UP) Ltd., Uttar Pradesh, for over three years. Dr. Dhara has authored more than ten research and review papers in reputed journals, along with fifteen book chapters and five books. He has presented his work at national and international conferences and is a life member of the Indian Pharmaceutical Association and Indian Pharmacological Society, as well as a registered pharmacist. Amit Kumar Nayak (M. Pharm, Ph.D) is currently working as Professor at School of Pharmaceutical Sciences,Siksha ‘O' Anusandhan (Deemed to be University), Odisha, India. He has earned his PhD from IFTM University, Moradabad, Uttar Pradesh, India. He has over 14 years of research experiences in the field of pharmaceutics, especially in the development and characterization of novel biopolymeric and nanostructured drug delivery systems. Till date, he has authored more than 138 research and review publications in various high-impact peer-reviewed journals and 135 book chapters. He has edited/authored 23 international books to his credit. Dr. Nayak has presented his research work at several conferences. He has received University Foundation Day Research Award, 2019 and 2022 by Biju Patnaik University of Technology, Odisha. Dr. Nayak is a life member of the Association of Pharmaceutical Teachers of India (APTI) and a registered pharmacist.

• Section I: Introduction1. Introduction to antiviral therapySection II: Viral infections and transmission2. Emerging viral diseases3. Evolution and transmission of viruses4. Mode of viral infections and transmissions5. Transmission and Intervention Dynamics of SARS-CoV-26. Sexually transmitted viral infections7. Testing of viral infections8. Electron microscopic methods for virus diagnosisSection III: Antiviral agents and therapeutics9. Virotherapy10. Challenges in designing antiviral agents11. Anti-influenza agents12. Anti-herpes virus agents13. Antiretroviral Therapies14. Rotavirus and anti-rotaviral agents: Trends and advances15. Current therapeutic strategies and novel antiviral compounds for the treatment of non-polio enteroviruses16. Antiviral agents against flaviviruses17. Pathophysiology of HIV and strategies to eliminate AIDS as a public health threat 18. Herbal drugs to combat viruses19. Strategies for delivery of antiviral agents20. Nanovesicles for delivery of antiviral agents21. Antiviral biomaterials22. Antiviral biomolecules from marine inhabitantsBalasubramanian 23. Plant polysaccharides as antiviral agents24. Antiviral peptides against dengue virus25. mRNA vaccines for COVID-1926. Immunotherapy as an emerging and promising tool against viral infections27. Role of nutraceuticals as immunomodulators to combat virusesSection IV: Others28. In vitro and in vivo approaches for evaluating antiviral efficacy29. Clinical trials and regulatory considerations of antiviral agents30. Future perspectives of antiviral therapy